Reuters logo
BRIEF-Novo reports positive results from phase 3 trial with NovoEight
March 19, 2014 / 12:40 PM / 4 years ago

BRIEF-Novo reports positive results from phase 3 trial with NovoEight

COPENHAGEN, March 19 (Reuters) - Danish pharmaceutical group Novo Nordisk A/S said on Wednesday: * Reports positive results from first phase 3 trial with N8-GP, a

long-acting factor VIII for treatment of haemophilia A patients, 12 years or older * N8-GP appeared to have a safe profile and to be well tolerated * Among the 186 patients in the trial, one patient who responded well to prophylactic treatment throughout the trial developed an FVIII inhibitor. This is in line with expectations in a population of previously treated haemophilia A patients. * Novo is expecting the three remaining trials in the programme to be finalised within the next 12 months. Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below